title: Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time.
abstract: OBJECTIVE
  To describe the persistent use of evidence-based cardiovascular medications (EBCMs) 3 months after discharge from an acute coronary syndrome (ACS) event and patient-reported reasons for nonpersistence across age groups.
  
  
  METHODS
  Medication Applied and Sustained Over Time (MAINTAIN) is a longitudinal follow-up cohort study of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation quality improvement initiative and Acute Coronary Treatment and Intervention Outcomes Network registry.
  
  
  METHODS
  Forty-one acute care hospitals in the United States from January 2006 to September 2007.
  
  
  METHODS
  One thousand fifty-four patients with a median age of 60 (interquartile range 52-71), including 27% aged 70 and older, admitted with an ACS.
  
  
  METHODS
  Three-month posthospital discharge telephone follow-up with EBCMs reviewed and reconciled. Patients who reported nonpersistence were surveyed regarding reasons for EBCM discontinuation.
  
  
  RESULTS
  At 3-month follow-up, overall persistence was 71.2%. There was a significant trend toward lower overall persistence with prescribed EBCMs in older adults than in the other age groups (74.9% for <60, 71.0% for 60-69, 64.5% for > or =70; P=.02). Overall, 112 (10.6%) patients discontinued EBCMs with provider advice, and 178 (16.9%) self-discontinued. Provider discontinuation increased across age groups (9.1%, 10.4%, and 13.6%, respectively). A similar trend was observed for EBCM self-discontinuation (15.2%, 17.0%, and 19.9%, respectively). Reasons for self-discontinuation included adverse effects, cost, and perception that the medication was not needed.
  
  
  CONCLUSIONS
  Older patients are less likely to be persistent with EBCMs after an ACS event at 3-month follow-up. Understanding patient-reported reasons for discontinuation can influence intervention strategies to improve long-term adherence to EBCMs.
authors.affiliation: Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. robin.ali@duke.edu
authors.forename: Robin C
authors.initials: RC
authors.lastname: Ali
authors.forename: Chiara
authors.initials: C
authors.lastname: Melloni
authors.forename: Fang-Shu
authors.initials: FS
authors.lastname: Ou
authors.forename: Kenneth
authors.initials: K
authors.lastname: Schmader
authors.forename: E Magnus
authors.initials: EM
authors.lastname: Ohman
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Roe
authors.forename: Eric D
authors.initials: ED
authors.lastname: Peterson
authors.forename: Karen P
authors.initials: KP
authors.lastname: Alexander
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000367:Age Factors; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D016527:Drug Costs; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data*; D010351:Patient Discharge; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012042:Registries; D055502:Secondary Prevention; D014481:United States
chemical_list: D002317:Cardiovascular Agents